Who are Abbott India's main competitors?

Named competitors: Sun Pharmaceutical (SUNPHARMA.NS), Cipla (CIPLA.NS), Pfizer India (PFIZER.NS), GlaxoSmithKline Pharmaceuticals (GLAXO.NS). The cockpit's measured peer set (industry) also includes Shanghai Allist Pharmaceuticals (688578.SS), Veradermics (MANE), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), Belite Bio, Inc. ADR (BLTE), Apotex Health (APTX.TO).

How has Abbott India stock performed?

Over six months to 6 Nov 2026 the shares returned -1.3% against -4.5% for the median peer; over one year -11.0%.

← CockpitCompetitor Analysis › ABBOTINDIA.NS Abbott IndiaOpen in the cockpit ↗

Abbott IndiaABBOTINDIA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian listed subsidiary of Abbott selling branded generic medicines and nutrition products, made mainly for the domestic market.

≈ Abbott Laboratories' majority-owned India-listed unitMomentum neutral 54

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$5.93B

US dollars, full cap

Free float

24%

of shares outstanding

$/day

$1.96M

20-day average traded

Fwd P/E

32.4×

forward earnings

ROIC−WACC

+20.9 pp

WACC 9.3%

Hurdle

+1 pp

Req g minus delivered

Next earnings

96 days

10 Feb 2027

Close · INR₹26,345

1D-1.0%

1W+2.8%

1M+1.0%

3M-5.4%

6M-1.3%

YTD-9.2%

1Y-11.0%

ATR %2.6%

Beta0.23

52w lowhigh14.1% off high

What Abbott India does

Indian listed subsidiary of Abbott selling branded generic medicines and nutrition products, made mainly for the domestic market.

Earns from prescription brands that doctors recommend and patients buy again and again from pharmacies through stockists, with chronic therapies such as thyroid and stomach treatments giving steady refills. A sales force calling on doctors, not advertising, drives volume. Abbott Laboratories of the US holds the majority and supplies new products from its global range.

In one line: Abbott Laboratories' majority-owned India-listed unit.

Products and services

Branded prescription formulations (Thyronorm, Digene)
Nutrition products
OTC brands

Customers

Indian retail pharmacies
Doctors/hospitals

Where it sits in the supply chain

Pharmaceuticals
Branded generics + nutrition (India)
Domestic distribution

What could go right

India's growing chronic-disease drug market
New product introductions from parent

What could go wrong

Price controls (NPPA)
Limited pipeline of its own

Moat: narrow (brand, distribution). Long-standing trusted brands (Thyronorm, Digene) with entrenched doctor prescribing habits.

Headquarters: Mumbai, India · Founded: 1944 · Employees: 3,749

Named competitors

Sun Pharmaceutical SUNPHARMA.NS
Cipla CIPLA.NS
Pfizer India PFIZER.NS
GlaxoSmithKline Pharmaceuticals GLAXO.NS

Abbott India at a glance

Size Abbott India (ABBOTINDIA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $5.93B, the 189th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹26,345 on 6 Nov 2026.

Performance Over six months the shares fell 1.3%, against -4.5% for the median peer and 0.0% for the India market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 6.3% over the last twelve months (peer median +10.6%); the operating margin is 27.5% (peer median 14.4%).

Valuation It trades at 32.4× forward earnings against a peer median of 28.0× (5th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 20.9 points above its cost of capital (9.3% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Abbott India against the median of its 20 peers (local-currency closes).

Abbott India financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₹70.0B	₹69.3B	₹64.1B	₹58.5B	₹53.5B
Revenue growth	—	+8%	+10%	+9%	—
Gross profit	₹26.0B	₹24.7B	₹22.2B	₹19.5B	₹17.1B
EBITDA	₹20.0B	₹19.4B	₹17.2B	₹14.8B	₹12.3B
Net income	₹16.1B	₹15.5B	₹14.1B	₹12.0B	₹9.49B
Free cash flow	n/a	₹16.6B	₹10.8B	₹13.1B	₹9.61B
Capital expenditure	n/a	₹409M	₹526M	₹483M	₹341M
Total debt	n/a	₹1.72B	₹1.97B	₹832M	₹1.13B

Quarterly statements and history in the cockpit →

Abbott India competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Abbott India is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Abbott India is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Abbott India is the large dot.

Abbott India competitors and peer comparison

Head to head with its named competitors (ABBOTINDIA.NS vs SUNPHARMA.NS vs CIPLA.NS vs PFIZER.NS)
Company	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g
Abbott India ABBOTINDIA.NS	$5.93B	-1%	+6%	28%	32.4×	11.4%
Sun Pharmaceutical Industries SUNPHARMA.NS	$47.3B	+1%	+12%	23%	35.4×	28.4%
Cipla CIPLA.NS	$12.1B	+4%	-1%	13%	29.0×	28.2%
Pfizer PFIZER.NS	$1.87B	-19%	+12%	34%	21.5×	11.2%
GlaxoSmithKline Pharmaceuticals GLAXO.NS	$4.53B	+2%	+12%	33%	35.9×	25.2%

How Abbott India compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Abbott India against its 20 peers (data as of 6 Nov 2026)
Measure	ABBOTINDIA.NS	Peer median	Rank in peer set
1-month return	+1.0%	+2.5%	9th lowest of 21
6-month return	-1.3%	-4.5%	10th highest of 20
Distance from 52-week high	-14.1%	-20.6%	8th highest of 21
Revenue growth (TTM)	+6.3%	+10.6%	8th lowest of 17
Operating margin	27.5%	14.4%	4th highest of 18
Forward P/E	32.4×	28.0×	5th most expensive of 16
Growth the price implies (Req g, 7 yrs)	11.4%	6.1%	6th most demanding of 13
Growth delivered (Del g)	+10.0%	+11.5%	6th lowest of 13
Hurdle (Req g minus delivered)	+1.5 pp	+0.2 pp	7th least demanding of 13
ROIC minus cost of capital	+20.9 pp	+1.3 pp	3rd highest of 18
EV / EBITDA	28.0×	20.8×	3rd most expensive of 10
Net debt / EBITDA	-1.0×	0.6×	3rd least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Abbott India ABBOTINDIA.NS	India	$5.93B	-1%	+6%	28%	32.4×	11.4%	+10.0%
Shanghai Allist Pharmaceuticals 688578.SS	China	$5.90B	-6%	+39%	47%	13.8×	1.8%	+519.6%
Veradermics MANE	United States	$5.80B	+31%	n/a	n/a	n/a	n/a	n/a
Mirum Pharmaceuticals MIRM	United States	$6.12B	-13%	+42%	-21%	n/a	n/a	n/a
Ligand Pharmaceuticals LGND	United States	$6.12B	+38%	+1%	14%	28.0×	57.8%	+7.5%
Belite Bio, Inc. ADR BLTE	United States	$6.20B	0%	n/a	n/a	n/a	n/a	n/a
Apotex Health APTX.TO	Canada	$5.62B	n/a	+4%	32%	18.6×	-13.5%	+4.2%
Biocon BIOCON.NS	India	$6.28B	-4%	+6%	8%	56.4×	n/a	n/a
Gland Pharma GLAND.NS	India	$5.53B	+69%	+18%	20%	39.0×	28.0%	+13.3%
Samsung Epis 0126Z0.KS	South Korea	$6.39B	-36%	n/a	-25%	24.0×	n/a	n/a
Gan & Lee Pharmaceuticals 603087.SS	China	$6.40B	+21%	+14%	20%	29.7×	n/a	n/a
PTC Therapeutics PTCT	United States	$5.47B	-11%	-35%	22%	34.8×	8.0%	+35.4%
Supernus Pharmaceuticals SUPN	United States	$5.43B	-49%	+16%	45%	6.7×	4.2%	+13.9%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ	China	$6.48B	0%	+4%	14%	12.8×	-6.3%	+18.4%
Ionis Pharmaceuticals IONS	United States	$6.55B	-48%	-7%	-68%	n/a	n/a	n/a
Alkem Laboratories ALKEM.NS	India	$6.67B	-5%	+13%	17%	27.4×	24.3%	+10.7%
Beijing TongRenTang 600085.SS	China	$5.27B	-8%	-17%	8%	31.2×	2.7%	+6.2%
Sumitomo Pharma 4506.T	Japan	$5.23B	+7%	+11%	10%	8.3×	1.4%	-2.6%
IPCA Laboratories IPCALAB.NS	India	$5.22B	+24%	+11%	17%	32.4×	17.8%	+12.2%
Shenzhen Salubris Pharmaceuticals 002294.SZ	China	$5.18B	-39%	+14%	11%	41.6×	15.5%	+9.7%
Oruka Therapeutics ORKA	United States	$6.81B	+59%	n/a	n/a	n/a	n/a	n/a

Questions

Who are Abbott India's main competitors?: Named competitors: Sun Pharmaceutical (SUNPHARMA.NS), Cipla (CIPLA.NS), Pfizer India (PFIZER.NS), GlaxoSmithKline Pharmaceuticals (GLAXO.NS). The cockpit's measured peer set (industry) also includes Shanghai Allist Pharmaceuticals (688578.SS), Veradermics (MANE), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), Belite Bio, Inc. ADR (BLTE), Apotex Health (APTX.TO).
Is Abbott India expensive compared with its peers?: On forward p/e it trades at 32.4× against a peer median of 28.0×, 5th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Abbott India stock performed?: Over six months to 6 Nov 2026 the shares returned -1.3% against -4.5% for the median peer; over one year -11.0%.